Study | Study Group | Positive QTF-G, % | Positive TST, % | Agreement, % | Kappa* | Patients, n |
---|---|---|---|---|---|---|
Matulis16 | RA, SpA, UA, other | NA | NA | 64 | 0.17 | 109 |
Cobanoglu20 | Chronic inflammatory diseases | 18 | 73 | NA | 0.18 | 51 |
Takahashi21 | RA | 28.5 | 28.5 | NA | NA | 14 |
Greenberg17 | RA | 18 | 21.3 | NA | NA | 61 |
Chen22 | RA | NA | NA | 60 | 0.21 | 35 |
Ponce de Leon10 | RA | 44.6 | 26.7 | 70.3 | 0.37 | 101 |
Bartalesi23 | Autoimmune diseases | 13 | 19 | 87.7 | 0.55 | 398 |
Bocchino24 | RA, PsA, UC, CD | 31.8 | 26 | NA | 0.26 | 69 |
RA: rheumatoid arthritis; SpA: spondyloarthropathies; UA: undifferentiated arthritis; PsA: psoriatic arthritis; UC: ulcerative colitis; CD: Crohn’s disease; QTF-G: Quantiferon-TB Gold test; TST: tuberculin skin test.
↵* For agreement between QTF-G and TST. NA: not available.